Overview

This trial is active, not recruiting.

Condition renal transplantation
Treatment taiz
Phase phase 1
Sponsor University of Schleswig-Holstein
Start date February 2004
End date August 2005
Trial size 10 participants
Trial identifier NCT00223093, 006

Summary

Induce tolerance or reduce the amount of immunosuppression after renal transplant patient (receiving cadaver kidney)with so called TAIZ-monocytes

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Primary Outcomes

Measure
graft survival
time frame:
replacement of immunosuppressives after treatment with Transplant-Acceptance Inducing Cells (TAIC)
time frame:
serum creatinine
time frame:
rejection episodes
time frame:
re-introduction of immunosuppressives.
time frame:

Secondary Outcomes

Measure
safety and tolerability of the treatment with Transplant-Acceptance Inducing Cells (TAIC) Adverse Events (AEs)
time frame:

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

4.3.1 Inclusion Criteria Patients must meet all the following inclusion criteria to be considered for admission to the trial: 1. Male or female adult patients aged between 18 and 64 years (inclusive). A female of childbearing potential may be enrolled provided she: - has a negative pregnancy test at Screening and - is routinely using adequate contraception prior to and during the study and - agrees not to attempt to become pregnant during the study and - is not lactating A female of non-childbearing potential will be defined as one who has been postmenopausal for at least one year or has been surgically sterilised. 2. Patients receiving a first renal transplant. 3. Patients who fulfil the criteria to receive an allogeneic renal transplant from a cadaver (according to the Eurotransplant (ET) manual on organ allocation and the Bundesärztekammer allocation criteria). 4. Patients who, after the nature of the study and the disclosure of their data has been explained to them, have freely given Informed Consent in writing. 4.3.2 Exclusion Criteria Patients presenting any of the following exclusion criteria must not be included in the trial: 1. Patients who have received a renal transplant. 2. Patients who have an active infection at the time of entry into the study (Screening). 3. Recipient and donor pairs who show the following incompatible CMV constellation: the donor is CMV positive and the recipient is CMV negative. 4. Patients and donor who have positive evidence of HIV or have active virus hepatitis B and C. 5. Patients with a history of alcohol and/or drug abuse. 6. Patients who are pregnant women or nursing mothers. 7. Known hypersensitivity or contraindication to one of the immunosuppressives administered during the course of the study: tacrolimus, sirolimus or steroids (prednisolone and methylprednisolone). 8. Patients with a history or present symptoms of autoimmune vasculitis. 9. Detection of >5% HLA antibodies (current values determined during the last three months). 10. Patients with a malignancy or history of malignancy. 11. Patients with renal insufficiency due to a vasculitis. 12. Recipient and donor pairs with complete HLA matching. 13. Patients whose condition requires continuous systemic steroid administration. 14. Patients who are simultaneously participating or plan to participate in any other clinical study. 15. Psychiatric or emotional problems or lack of knowledge of the German language which would invalidate the giving of Informed Consent or limit the ability of the subject to comply with study requirements. 16. Unwillingness or inability to provide Informed Consent or to participate satisfactorily for the entire trial period

Additional Information

Official title A Single-Center Open-Labelled Study of the Administration of Transplant-Acceptance Inducing Cells (TAIZ) for the Induction of Donor Specific Tolerance in Renal Allograft Recipients (Cadaver Kidney)
Principal investigator Ulrich Kunzendorf, MD
Trial information was received from ClinicalTrials.gov and was last updated in October 2005.
Information provided to ClinicalTrials.gov by University of Schleswig-Holstein.